Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Raffaella Palumbo,Federico Sottotetti,Erica Quaquarini,A. Gambaro,Antonella Ferzi,B. Tagliaferri,C. Teragni,Luca Licata,Francesco Serra,Pietro Lapidari,Antonio Bernardo

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

2019

Raffaella Palumbo
Federico Sottotetti
Erica Quaquarini
A. Gambaro
Antonella Ferzi
B. Tagliaferri
C. Teragni
Luca Licata
Francesco Serra
Pietro Lapidari
Antonio Bernardo

Background:Fulvestrant 500 mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding the ...

Keywords:

HER2 negative
Hormone receptor
Pharmacology
Fulvestrant
Oncology
Metastatic breast cancer
Medicine
Internal medicine
Metastasis
Population
Disease
Pathology
Cohort study
Chemotherapy
Endocrine system

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations